Interferon‐γ inducible protein 30 promotes the epithelial–mesenchymal transition‐like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β‐catenin pathway in glioma

Abstract

AimsPrevious studies have indicated that IFI30 plays a protective role in human cancers. However, its potential roles in regulating glioma development are not fully understood.MethodsPublic datasets, immunohistochemistry, and western blotting (WB) were used to evaluate the expression of IFI30 in glioma. The potential functions and mechanisms of IFI30 were examined by public dataset analysis; quantitative real‐time PCR; WB; limiting dilution analysis; xenograft tumor assays; CCK‐8, colony formation, wound healing, and transwell assays; and immunofluorescence microscopy and flow cytometry.ResultsIFI30 was significantly upregulated in glioma tissues and cell lines compared with corresponding controls, and the expression level of IFI30 was positively associated with tumor grade. Functionally, both in vivo and in vitro evidence showed that IFI30 regulated the migration and invasion of glioma cells. Mechanistically, we found that IFI30 dramatically promoted the epithelial–mesenchymal transition (EMT)‐like process by activating the EGFR/AKT/GSK3β/β‐catenin pathway. In addition, IFI30 regulated the chemoresistance of glioma cells to temozolomide directly via the expression of the transcription factor Slug, a key regulator of the EMT‐like process.ConclusionThe present study suggests that IFI30 is a regulator of the EMT‐like phenotype and acts not only as a prognostic marker but also as a potential therapeutic target for temozolomide‐resistant glioma.

Identification and validation of a novel signature based on macrophage marker genes for predicting prognosis and drug response in kidney renal clear cell carcinoma by integrated analysis of single cell and bulk RNA sequencing

“…It has been reported that IFI30 can promote the EMT process in glioma cells by activating EGFR/AKT/GSK3β/β-catenin. In addition, IFI30 directly modulates drug resistance in glioma cells [ 17 ]. Fan et al elaborated that IFI30 is highly expressed in breast cancer and is associated with poor prognosis, and that it can affect breast cancer cell proliferation by regulating autophagy [ 18 ].…”

Identification of monocyte-associated biomarkers in systemic lupus erythematosus and their pan-cancer analysis

“…IFI30 overexpression, which is associated with a poor prognosis in glioma, is positively correlated with tumor grade and may mediate a mechanism of decreased sensitivity to chemotherapy. 25,26 IFN-γ is a key factor in the induction and sustained expression of immune checkpoints in tumor cells of several tumor types including non-small cell lung cancer and skin melanoma, gastric cancer, and glioma. [27][28][29] RIN2 expression increases stepwise in Barrett's esophagus, Barrett's esophagus with dysplasia, and esophageal adenocarcinoma, and it can be used to detect prevalent and inconspicuous heterogeneous hyperplasia and early tumors in Barrett's esophagus.…”

Expression, Prognostic Value, and Biological Function of CTHRC1 in Different Types of Gliomas: A Bioinformatic Analysis and Experiment Validation

“… 4 - 6 Studies have found a correlation between glioma progression and epithelial-mesenchymal transition (EMT), which promotes tumor proliferation, invasion, and treatment resistance. 7 - 9 Therefore, the identification of EMT-related genes associated with glioma invasion is of significant importance for the clinical treatment of gliomas.…”